Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Atea Pharmaceuticals, Inc. (AVIR : NSDQ)
 
 • Company Description   
Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON.

Number of Employees: 56

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.62 Daily Weekly Monthly
20 Day Moving Average: 399,572 shares
Shares Outstanding: 85.58 (millions)
Market Capitalization: $310.23 (millions)
Beta: 0.25
52 Week High: $4.15
52 Week Low: $2.46
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 12.23% 7.60%
12 Week 32.30% 15.93%
Year To Date 8.21% 2.20%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
225 Franklin Street Suite 2100
-
BOSTON,MA 02110
USA
ph: 857-284-8891
fax: -
investors@ateapharma.com http://www.ateapharma.com
 
 • General Corporate Information   
Officers
Jean-Pierre Sommadossi - President; Chief Executive Officer and Chairman
Andrea Corcoran - Chief Financial Officer and Executive Vice Preside
Wayne Foster - Executive Vice President; Chief Accounting Officer
Franklin Berger - Director
Jerome Adams - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04683R106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
Share - Related Items
Shares Outstanding: 85.58
Most Recent Split Date: (:1)
Beta: 0.25
Market Capitalization: $310.23 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.81 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.13 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.75
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 46.67%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -31.26
12/31/24 - -35.86
ROA
06/30/25 - -
03/31/25 - -29.27
12/31/24 - -33.36
Current Ratio
06/30/25 - -
03/31/25 - 19.94
12/31/24 - 24.85
Quick Ratio
06/30/25 - -
03/31/25 - 19.94
12/31/24 - 24.85
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 4.80
12/31/24 - 5.20
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©